Aims-To examine the effectiveness of prophylactic intravenous indomethacin in reducing the mortality and morbidity associated with patent ductus arteriosus and intraventricular haemorrhage in infants weighing less than 1750 g at birth. Method-A literature search from 1980 onwards was made of three databases: Medline; Embase; and the Oxford Database of Perinatal Trials. Using strict criteria applied to randomised controlled trials only, two observers independently selected 14 studies for inclusion in the review. The methodological quality of each study was assessed independently by two observers using explicit criteria. Data on relevant outcome measures were extracted on two separate occasions. Where appropriate, the results of individual trials were combined using metaanalysis techniques to provide a pooled estimate of effect. Results-There is a trend towards reduced neonatal mortality in infants receiving prophylactic indomethacin, pooled estimate of risk difference -0 025 (95%/ confidence interval (CI) -0-061, 0-010). The incidence of symptomatic patent ductus arteriosus is significantly reduced in treated infants, pooled estimate of risk difference -0*217 (95°/0 CI -0*275, -0-160), but there is no evidence that treatment affects respiratory outcomes. Prophylactic indomethacin significantly reduces the incidence of grades 3 and 4 intraventricular haemorrhage in treated infants, pooled estimate of risk difference -0-039 (950/. CI -0-066, -0.011). However, there is no sound evidence assessing the long term effect of prophylaxis on neurodevelopmental outcome.
estimate of effect. Results-There is a trend towards reduced neonatal mortality in infants receiving prophylactic indomethacin, pooled estimate of risk difference -0 025 (95%/ confidence interval (CI) -0-061, 0-010). The incidence of symptomatic patent ductus arteriosus is significantly reduced in treated infants, pooled estimate of risk difference -0*217 (95°/0 CI -0*275, -0-160), but there is no evidence that treatment affects respiratory outcomes. Prophylactic indomethacin significantly reduces the incidence of grades 3 and 4 intraventricular haemorrhage in treated infants, pooled estimate of risk difference -0-039 (950/. CI -0-066, -0.011). However, there is no sound evidence assessing the long term effect of prophylaxis on neurodevelopmental outcome. Although there is a trend in treated infants towards an increased incidence of necrotising enterocolitis, pooled estimate of risk difference 0*015 (95%/. CI -0*002, 0.033), and some evidence that treatment may transiently impair renal function, there is no evidence that haemostasis is disturbed. Conclusion-Prophylactic treatment with indomethacin has several immediate benefits. However, more data are needed on the incidence of possible adverse effects and neurodevelopmental outcomes before routine use of this therapy can be recommended.
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Premature infants with a patent ductus arteriosus (PDA) are at increased risk of more prolonged and more severe respiratory distress syndrome, bronchopulmonary dysplasia, and death compared with similar infants whose ductuses have closed.' This prompted surgical intervention2 and, later, pharmacological treatment using indomethacin3 in an attempt to improve the outcome in these infants. Because treatments that closed the patent ductus potentially influence the pulmonary circulation, the early outcomes examined included measures of ventilatory support, pneumothorax, chronic lung disease and mortality. It was subsequently suggested that medical treatment, comprising a variety of mechanisms,-6 might prevent intraventricular haemorrhage (IVH) .
Treatment with prophylactic indomethacin may, however, be associated with serious adverse effects. By reducing cerebral blood flow, indomethacin may increase the risk of cerebral hypoxia.7 It remains essential, therefore, to consider long term neurodevelopmental outcomes, as this potential adverse effect may outweigh any benefit from a possible reduction in the incidence of intraventricular haemorrhage. Similarly, although closure of the patent ductus may be expected to reduce the incidence of necrotising enterocolitis, this needs to be balanced against any effect indomethacin might have directly on gut blood flow.8 Indomethacin may also reduce renal blood flow, thus impairing renal function.9 It may interfere with platelet aggregation, thus impairing haemostasis. I0 If there is a potential effect on the microvasculature and cerebral blood flow the incidence of retinopathy of prematurity may be affected by treatment. Finally, there has been at least one report of indomethacin being associated with an increased risk of sepsis. "I Potential adverse effects must be considered, particularly when assessing the overall effect of prophylaxis. Only some infants will F82 Fowlie ever actually experience a patent ductus arteriosus and/or intraventricular haemorrhage, and it is only this proportion of the infant population that could benefit from prophylaxis. However, as all infants would be exposed to the treatment through prophylaxis, all of them would be exposed to possible harm. Using the evidence of individual trials to date, neonatologists are uncertain about the benefit(s) of prophylaxis, if any, and remain concerned in case this intervention might, in fact, do more harm than good.
One method of summarising evidence that can provide a more accurate and precise estimate of treatment effect, by minimising the bias and random error which can influence the results of individual trials, is the systematic review of all known trials.12 A systematic search for reviews of prophylaxis in very low birthweight infants failed to identify any that provided explicit details of how the review was conducted. This study, therefore, presents the methods and results of a systematic review and, where appropriate, meta-analyses of the evidence examining the effectiveness of prophylactic indomethacin in reducing mortality and morbidity in infants weighing less than 1750 g at birth. To be included in the review, trials had to meet each of four criteria * the study infants had to be newborn with a maximum birthweight of 1750 g (studies with a lower weight limit were also included) * the intervention had to be prophylactic treatment with intravenous indomethacin given within 24 hours of birth * the study had to be a randomised controlled trial * the study had to include some measure of at least one of the outcomes listed in table 1 Each of the 68 available articles identified by the literature search was assessed independently, using the inclusion criteria, by the author and a colleague training in research methodology. Agreement beyond chance on which articles to include or exclude was measured using Cohen's kappa (0 93) statistic and any disagreement was resolved by discussion. In this way 19 articles/abstracts were initially selected for inclusion in the review.
Methods
As yet, there is no universally accepted way to assess the methodological quality (validity) of clinical trials.'3 For this study, having preselected only randomised controlled trials, the author chose to base validity assessment on four methodological criteria that can be associated with significant bias in trials assessing treatment effect. 14 ( No scoring system is incorporated in this particular method of quality assessment. The final interpretation of the validity of the studies included in the review is, therefore, left to the individual reader.
On the basis of the four criteria described above, the same two investigators that selected the articles for inclusion independently assessed the methodology reported in each article/abstract. For each of the four criteria, agreement beyond chance, measured by Cohen's kappa, was as follows: method of treatment allocation, 0-73; blinding of care giver, 0 90; >90% follow up, 0-51; and blinding of person assessing outcome, 064. Disagreement was settled by discussion. Sixty six per cent of disagreement was found to be due to simple misreading.
Each article was reviewed by the author and the outcomes measured were recorded, initially without specific data. On two separate occasions the data were then extracted from the articles/abstracts and checked for consistency. Any discrepancies were resolved by a third data extraction. The data taken from abstracts were compared with data taken from full manuscripts by the same author(s) to try *Dosage schedule changed to 0 1 mg/kg/doseX 5 early in trial after concern about diminished urine output in treated infants. tThis abstract reports neurodevelopmental follow up on 123 of the 199 infants enrolled in the trial more fully reported by Bandstra in 1988. and avoid duplicating data. On the basis of the date of the study, the size of the treatment and control groups, and the raw data available, five abstracts15-19 were thought to provide data subsequently published in a full manuscript. All five abstracts, none of which contributed any unique data, were therefore dropped from the review. Dichotomous outcomes are expressed in three ways. The event rate ratio (ERR) is the event rate in the treatment group as a proportion of the event rate in the control group. The event rate difference (ERD) is the difference in event rate between the treatment group and the control group. The number needed to treat (NNT) is the inverse of the event rate difference, and is the number of subjects that one expects will need to be treated to prevent one subject having the adverse outcome. A fixed effect model is used to calculate the pooled event rate ratio and the pooled event rate difference.20 Continuous The results shown in table 4 show there is no significant difference in neonatal mortality between the treatment and placebo groups. However, the confidence intervals around the pooled estimates suggest a trend toward a reduction in mortality in those infants treated with prophylactic indomethacin.
PATENT DUCTUS ARTERIOSUS Prophylactic indomethacin reduces the incidence of 'symptomatic' PDA (PDA associated with signs/symptoms of congestive heart failure) (table 5). The incidence of echo-diagnosed PDA -that is, the sum of all patent ductuses whether symptomatic or not, is reduced even further by prophylactic indomethacin (five trials,24 31 The incidence of IVH of all grades is significantly reduced in infants who receive prophylactic indomethacin (table 6 ). An analysis of the trials providing data on grades 3 and 4 haemorrhage shows this effect is still present and the incidence of severe IVH is reduced in the treatment group by about 40%/o (table 7) .
There is no evidence, however, that prophylactic indomethacin reduces the incidence of intraventricular haemorrhage (grade 1) that progresses (two trials,33 34 NEURODEVELOPMENTAL OUTCOME
The effect of prophylactic indomethacin on long term neurodevelopmental outcome has been described only by Bandstra (abstract).32
There is no evidence of a significant difference between the treatment and placebo groups when assessed using the Bayley Mental and Physical Developmental Index at between 12 and 24 months, although Bandstra reported a trend toward a lower incidence of abnormal physical scores in the indomethacin group.
NECROTISING ENTEROCOLITIS
The pooled estimates of the effect on the incidence of necrotising enterocolitis do not quite (95% CI -0-028, -0 025). Mahoney23 reported mean serum sodium, potassium, and creatinine on day 3 as well as mean urine output over the first four days. There is no significant difference between the groups in any of these measures. Vincer26 reported mean serum sodium concentrations over the first seven postnatal days and points to a significantly higher concentration in the treatment group on days 3 and 4. In addition to reporting reduced urine output in the treatment group, Rennie27
reported significantly higher peak creatinine on days 1 and 2 following treatment with indomethacin, but no significant difference in serum sodium concentrations. Krueger29
reported a significant reduction in urinary output (as measured by the input:output ratio) affecting the treatment group in the 24 hours immediately following treatment. This difference is no longer apparent in the subsequent 24 hour period. In 1988, Ment reported no clinically important renal abnormalities but provides no data.3' Bada33 provided data that show significant changes in plasma creatinine and sodium concentrations, osmolalities, and urine output, but comments that these differences were not abnormal -that is, not clinically important.
HAEMOSTASIS
Ment reported the number of infants whose platelet count fell to <50x 109/l. The pooled result shows no evidence of a difference between the treatment and placebo groups (two trials,34 35 492 infants); pooled ERR=0-502 (95% CI 0d113, 2-221); pooled ERD=-0 009 (95% CI -0030, 0.012). In the same two trials Ment also reported the number of infants who had 'excessive bleeding' and again the pooled result suggests no difference: pooled ERR=0-860 (95% CI 0 397, 1-856); pooled ERD=-0004 (95% CI -0-042, 0 032). Setzer22 provided data showing that platelet count is reduced and bleeding time prolonged following both active treatnent and placebo. The data are analysed within subjects only and do not permit a reliable comparison between groups. Rennie27 suggested that treatment with indomethacin prolonged bleeding time. However, no direct comparison between the indomethacin group and the control group is offered and the data given do not permit further analysis.
RETINOPATHY OF PREMATURITY
There is no evidence of a difference in the rates of retinopathy of prematurity between treatment and placebo groups (three trials,23 24 32 
SEPTIC EPISODES
There is no evidence that prophylactic indomethacin has a significant effect on the incidence of septic episodes (two trials,23 32 303 infants); pooled ERR=0-743 (95% CI 0-478, 1-154); pooled ERD=-0 059 (95% CI -0 150, 0030).
HETEROGENEITY AMONG TRIALS
Some degree of clinical heterogeneity would not be unexpected, given that most of the studies reviewed are relatively small and there is obvious variation in study design (particularly birthweight eligibility criteria, the indomethacin dosage regimes used, and some of the outcome definitions). In fact, when considering the main apparent benefits of indomethacin -reduced incidence of IVH and PDA, the results of the trials examined seem, clinically, fairly homogeneous. The results on potential adverse effects of prophylaxis are more heterogeneous, however, suggesting caution should be used when interpreting any pooled estimates. Embase of which just three were unique to that database. None of these three unique reports was ultimately included in the review. In this study, therefore, Embase was not a sensitive database for identifying randomised controlled trials in neonatology.
Using strict criteria, two investigators independently and under blind conditions, selected and assessed the quality of articles for inclusion in this review. This technique, particularly when associated with a high degree of agreement between the investigators as in this study, greatly strengthens the validity of the results of systematic reviews. The same methodology or a similar approach should be a standard requirement in all scientific overviews.
No attempt was made to trace unpublished data and this is a potential source of bias in the review. In addition, even after combining trials where appropriate, the number of infants providing data on certain outcomes reported remains very small. As a result, although no evidence of a significant difference can be shown for some outcomes, this may be because of a lack of statistical power rather than the absence of a true treatment effect. This is reflected in the very wide 95% confidence intervals around some of the pooled estimates. On the other hand, achieving significance does not necessarily equate with clinical importance, and some of the significant differences seen between the treatment and placebo groups, especially in renal function parameters, are of doubtful clinical importance.
The methodological quality of the trials contributing to this review varied. Although eight of the studies fulfilled more than two of the four validity criteria, two (both reported in abstract only) did not fulfil any. No account of this was taken in the analyses presented here and future work might include using techniques in the meta-analysis that try to adjust for this variation. It is also not clear what effect the inclusion of abstracts has on any pooled estimates of treatment effect, regardless of their methodological quality as reported. Three abstracts were included in this review, two of which contributed data towards pooled estimates. Although both were reporting relatively small studies and might, therefore, be expected to have relatively little impact on the relevant pooled estimates, this needs to be confirmed. The trials also vary considerably in the total dose of indomethacin used (0O2 mg/kg-0 6 mg/kg). If higher doses were found to be more effective, it might also be that higher doses were associated with more adverse side effects. This may then have implications when trying to determine the overall impact of treatment and needs further investigation.
Clinically, using the number needed to treat, this study suggests that if 100 infants were to be treated with prophylactic indomethacin, one might expect to see eight fewer infants with intraventricular haemorrhages (four of grades 3 or 4), 24 fewer infants with a PDA (20 of which were symptomatic), and possibly a reduction in overall neonatal mortality. This apparent benefit would be at the 'expense' of having five 'extra' infants with an episode of reduced urine output and, perhaps, an increase in the incidence (indeterminate at this time) of necrotising enterocolitis. Unfortunately, there are virtually no data reporting long term outcomes. Just one study (reported in abstract form) provides data on neurodevelopmental outcome on babies at between 12 and 24 months of age. The results are inconclusive and very difficult to interpret given the small number of infants contributing data and the nature of the report.
Conclusion
Although there is evidence to suggest immediate benefit, prophylactic indomethacin cannot yet be recommended for routine use. More data are needed on long term neurodevelopmental outcomes and possible adverse effects, especially the incidence of necrotising enterocolitis and clinically important episodes of impaired renal function. Future investigation, either new trials or further assessment of infants enrolled in previous studies, should be specifically directed at collecting these data as well as determining an optimal dosage regimen. Subgroup analyses on the basis of birthweight, gestation, and perhaps initial illness severity would also be worthwhile. 
